PTC Therapeutics
PTCT
184 hedge funds and large institutions have $2.09B invested in PTC Therapeutics in 2019 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 69 increasing their positions, 55 reducing their positions, and 26 closing their positions.
39% more call options, than puts
Call options by funds: $39.3M | Put options by funds: $28.4M
31% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 26
25% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 55
5% more funds holding
Funds holding: 176 → 184 (+8)
0.69% more ownership
Funds ownership: 99.91% → 100.6% (+0.69%)
20% less capital invested
Capital invested by funds: $2.63B → $2.09B (-$532M)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$72M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$54M |
| 3 |
RI
RTW Investments
New York
|
+$22.4M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$20.1M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$16.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$45M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11.5M |
| 3 |
State Street
Boston,
Massachusetts
|
-$10.4M |
| 4 |
Renaissance Technologies
New York
|
-$10.4M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$7.95M |
PTCT Hedge Fund Activity: Q3 2019 in Review
184 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q3 2019, worth a combined $2.09B — down 20% from $2.63B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new PTCT positions and 26 closed out — a net gain of 8 holders — while 69 added to existing stakes and 55 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $72M. The largest seller was Millennium Management, cutting an estimated $45M.
- 184 institutional investors held PTC Therapeutics (PTCT) as of Q3 2019, up from 176 in Q2 2019.
- Funds reported $2.09B of PTC Therapeutics stock for Q3 2019, down 20% quarter-over-quarter.
- 34 funds opened new PTC Therapeutics positions in Q3 2019 and 26 closed out, a net change of +8 holders.
- The largest PTC Therapeutics buyer in Q3 2019 was PFM Health Sciences, an estimated $72M added.
- The largest PTC Therapeutics seller in Q3 2019 was Millennium Management, an estimated $45M sold.
Based on aggregated 13F filings for Q3 2019.